Background
Type 2 diabetes mellitus (T2DM) individuals are more prone to microvascular complications such as (CKD) that is associated with increased morbidity, mortality and progression to end-stage renal disease.
1 Diabetes and hypertension are listed as major causes of CKD which is particularly important in developing countries such as Pakistan. 2 Up to 80 per cent of CKD patients have hypertension which significantly contributes to the progression of kidney disease toward end stage renal disease (ESRD). The National Kidney Foundation clinical practice guidelines (NKF-KDOQI) recommended a blood pressure goal of <130mmHg systolic and <80mmHg diastolic for all CKD patients. 3 Proteinuria is calculated by albuminto-creatinine ratio (ACR) and protein-to-creatinine ratio (PCR) is used to predict renal disease progression. 4 Anti-hyperglycemic treatment options for CKD patients with T2DM are limited because of the safety and tolerability concerns such as metformin being contraindicated in patients with creatinine clearance <60mL/min.
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Dipeptidyl peptidase 4 inhibitors (DPP4i) are well-tolerated treatment options for T2DM patients with any degree of renal impairment. [9] [10] [11] [12] These agents lower blood glucose by inhibiting the DPP-4 enzyme that controls GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) degradation. These hormones improve the control of glucose-dependent secretion of insulin and suppress glucagon secretion as shown in Figure 1 .
Dipetidyl peptidase enzymes limit the action of these chemicals and lead to rapid inactivation 13 Studies have suggested some links between obesity and an increased expression of DPP-4 enzymes which highlights the pathophysiological role which these enzymes can play in diabetes. [14] [15] This is a desirable effect when insulin secretion and glycaemic control is required 16 ). 20 Clinical studies have suggested that DPP-4i can offer some degree of nephroprotection. Previous studies using saxagliptin and linagliptin suggested an involvement of DPP4 in nephroprotection. This appears to be via a pathway independent of glycaemic control, such as the improvement of albuminuria. 21 Alogliptin is a DPP-4i that is used in T2DM treatment. 22 There is a dearth of studies that specifically compare DPP-4i usage in comparison to other anti-diabetic drugs for CKD and hypertensive patients. CKD In patients with eGFR ≥60mL/min there is no need for dose adjustment of alogliptin but in patients with eGFR 30-60 and <30mL/min it is reduced to 12.5mg and 6.25mg/daily respectively. [23] [24] Glycaemic control can be evaluated by analysing long term markers such as HbA1c and short term markers such as 1,5-anhydroglucitol (1,5-AG). 25 In patients with kidney disease, the levels of 1,5 AG are overall stable and is used in our hospital as a short glycemic marker. Thus, 1,5 AG of patients were recorded in this study. 26 The aim of the present study was to retrospectively evaluate T2DM with established mild CKD (eGFR 60-89mL/min/1.73m
2 ) and hypertension. Patient records were divided into two treatment groups; Group SU who received only SU (gliclazide) and Group SU+DPP-4i who received alogliptin in combination with gliclazide. Eligible patients were assessed for the levels of glycated hemoglobin (HbA1c), fasting blood glucose (FBG), 1,5-AG, eGFR and post prandial blood glucose (PPBG) for 12 months.
Method
This was a retrospective observational exploratory study performed in patients attending the Renal Unit at Punjab Care hospital, Lahore, Pakistan from February 2014 till April 2015. The study protocol was approved by the Ethics Committee of Punjab Care hospital, Lahore, Pakistan (IP-45603). The study was performed in accordance with Good Clinical Practice standards and the ethical principles that have their origin in the Declaration of Helsinki.
The selection criteria for the study population were as follows. All patients had a confirmed history ofT2DM which was evident by blood glucose and HbA1c levels (6.5-8.0% at screening). The mean±SD estimated duration of diabetes in group SU and SU+DPPi4 is 10.1±7.6, and 11.9±2.6, respectively. All patients had established CKD stage 1 (eGFR 60-89ml/min/1.73m 2 ; using the Modification of Diet in Renal Disease equation) and a history of established hypertension as evident from patient medical reports were included.
Patients who were on dialysis or likely to require dialysis during the study duration were excluded. All patients had been diagnosed with mild CKD based on the presence of proteinuria evidenced by ACR >2.5/3.5mg/mmol and PCR>15mg/mmol. Patients on insulin treatment or have received insulin within 12 weeks prior to screening, and patients with type 1 DM were excluded. In addition, patients with a history of ketoacidosis, acute renal disease, renal transplant, presence of liver disease, a cardiovascular event within 12 weeks, pregnancy and those who had received DPP-4i therapy within the previous 12 weeks = were also excluded.
Besides, patients with triglcyerides >600mg/dL were also excluded from the study.
The study population consisted of a total of 76 patients (38 males and 38 females) of age range 40-60 years who visited the hospital from February 2014 till April 2015.
Patient records were examined in detail for information such as any medical history, smoking habits, body mass index and physical examinations. Laboratory test records for the following parameters; fasting blood glucose (FBG), HbA1c levels, lipid profile and eGFR were recorded.
Selected diabetic patients with CKD and hypertension were divided into two groups. Each group had 38 individuals. Each patient either received gliclazide monotherapy (Group SU), or Alogliptin (DPP-4i) plus gliclazide (Group SU+DDP4i) add on therapy. Outpatient visits were scheduled at 3, 6, and 12 months during the first year of the study. All patients were followed up for 12 months for any arising renal complication.
Group SU received an oral dose of twice daily 60mg gliclazide, a (SU) monotherapy (Diamicron® MR 60mg; Servier, Pakistan) as prescribed by the patient's physician. According to the American Society's recommendations 60mg gliclazide would adjust the level of HbA1c to ≤6.5%. Group SU+DPP4i had received an add on therapy of a twice daily dose of 60mg gliclazide (SU) (Diamicron® MR 60 tablets; Servier, Pakistan) plus an oral once daily 12.5 mg dose of Alogliptin; a DPP-4i (Nesina 25mg; Takeda, Thailand).
During treatment and follow-up periods, patients had received standard medications for CKD and antihyperlipidemic drugs that are listed in Table 1 . Replacement or altered dosage of anti-hyperlipidemic drugs was not observed.
During the first year of the observational study, outpatient visit records at 3, 6, and 12 months were examined in detail. All patients had been followed up for renal complications. At each outpatient visit patients' glycated hemoglobin (HbA1c), fasting blood glucose (FBG), blood pressure, serum creatinine, 1,5 AG levels, urea, electrolytes and eGFR were obtained from the patients' medical records.
Statistical analysis
Package for Social Science (SPSS) Version 21 (SPSS Inc., Chicago IL, USA) was used for statistical analysis. The two treatment groups were compared using paired t-test and the calculated p-value was considered to be significant if it was ≤0.05. The effect size has been calculated for mean±SD GFR values.
Results
A total of 76 patients (38 males and 38 females) of the age range 40-65 were selected. Patient records were divided into two treatment groups.
Group SU had 38 individuals (19 females and 19 males) with mean±SD age (yr) and weight (kg) of 62.9±6.1, and 75.2±4.1, respectively. Group SU+DPP-4i had 38 patients (19 females and 19 males) with mean±SD age and weight of 58.9±7 and 85.5±75.1 respectively. The baseline demographic and clinical characteristics of both groups are provided in Table  1 . No statistical significance was noted in all baseline characteristics.
Glycemic control
Initially, the diabetes profile of the patients in Group SU and Group SU+DPP-4i showed no significant difference in HbA1c and FBG levels prior to treatment administration as represented in Figures 2 and 3 , respectively.
There was a significant difference in HbA1c and FBG between both groups after treatment administration as presented in Table 2 .
The levels of HbA1c, FBG and PPBG in Group SU+DPP-4i were significantly lower (p<0.05) when compared to Group SU (Figures 1-3) . As shown in Figure 3 the decrease in FBG was 57.1±16.8, 67.35±20.6mg/dl for Group SU and Group SU+DPP4i respectively. As shown in Figure 2 , the mean±SD decrease from baseline in HbA1c for Group SU and Group SU+DPP-4i were1.0±0.48 and 2.06±0.19%., respectively. In Figure 3 the decrease in PPBG was 5.1±3.6 and 16.35±0.1mg/dl for Group SU and Group SU+DPP4i respectively.
As shown in Figure 4 , comparing 1,5 AG (µg/mL) values at baseline and post 3, 6 and 12 months of treatment (n=76) between Group SU and Group SU+DDP-4i approached a significant difference at (p<0.001) 3 months and 12 months post-treatment but not at 6 months. Overall, the level of 1,5 AG was significantly higher in the Group SU+DPP-4i compared to SU group. Table 2 , comparing the lipid profile (LDL, HDL and TG) of individuals in Group SU and Group SU+DDP-4i showed significant difference (p<0.05) at baseline, 3 months and 6 months. However it normalized 12 months posttreatment.
Lipid control As shown in

Renal outcomes
The ACR and PCR values (mg/mmol) showed a mild nonsignificant decrease in both Groups. The mean±SD decrease from baseline in ACR and PCR for Group SU and Group SU+DPP-4i were 2.1±1.2 and 1.7±0.6mg/mmol, respectively.
As seen in Figure 5 , the eGFR values in the Group SU+DPP-4i compared to Group SU were significantly increased (p<0.05) at 6 months, 9 months and 12 months post-treatment.
The mean±SD decrease from baseline in ACR and PCR for Group SU and Group SU+DPP-4i were respectively 0.1±0. 13 Table 2 . All values are in Mean±SD. In terms of hypoglycaemia, there were two hypoglycaemic events reported in a total of two patients (one events in each patient) (2.5%).
Discussion
T2DM patients are often plagued by microvascular complications such as CKD and yet there is a lack of studies about the effects of DPP-4i in such patients.
In the present study we assessed the effect of alogliptin (DPP-4i) plus gliclazide (SU) in patients with T2DM, mild CKD and hypertension compared to patients who only received gliclazide (SU).
Glycaemic control and hypoglycaemic episodes
The present study showed that using alogliptin as add on therapy to gliclazide caused a significant (p<0.05) reduction in HbA1c and FBG levels when compared to Group SU monotherapy. This is in line with other studies that have shown better glycaemic control when adding DPP-4i therapy to metformin, insulin or sulfonylureas. 27 In the present study the level of 1,5-AG was measured as a short term marker for glycemic control since it has been found to be a more sensitive tool to check day to day glycemic control. 28 The 1,5-AG values and postprandial glucose levels showed an overall decrease and this tendency toward improvement suggested the possibility that alogliptin might improve postprandial hyperglycaemia. Speculation that DPP-4 inhibitors would improve blood glucose variability by suppressing postprandial hyperglycaemia requires more extensive studies to explore this aspect.
In fact 1,5-AG levels have also been linked to renal damage induced hyperglycaemia, where the increase in renal damage in diabetes patients was found to be more strongly related to 1,5-AG, than to FBG or HbA1C levels. In our study, 1,5-AG, appeared to be an attractive marker for not only detecting glycaemia severity but also for detecting renal damage induced hyperglycemia. 29 In both treatment groups, there were minor differences in hypoglycaemia incidences. This difference was not significant in our results but previous studies have shown that sulfonyl urea treated patients can often experience significant hypoglycaemic episodes. 30 Thus SU drugs should be used with caution at the lowest effective dosage and ongoing glucose level monitoring has been recommended for patients on this therapy regimen. However, DPP-4i treatment regimens have not been linked to significant hypoglycaemic episodes and this could be due to its effect on glucagon suppression during meal consumption and persistent glucagon suppression during hypoglycemia. 31 Thus, alogliption use may offer a potential add on therapy for patients diagnosed with other type of diabetes such as type 1 without significantly increasing the risk of hypoglycaemic episodes.
Blood pressure, lipid profile and BMI
Our results showed a significant improvement in the lipid profile (HDL, LDL and TG) when alogliptin was used in Group SU+DPP-4i in time points three, six, nine and twelve months. This suggests using alogliptin can improve the lipid profile of T2DM patients. This is of particular importance when considering an increased cardiovascular complication risk in T2DM patients. 32 Our results agree with a previous study that showed improvement in lipid profile when using alogliptin. 33 Mechanisms to explain this effect include GLP-1 induced myocardial protection, anti-inflammatory role by reduction of C reactive protein levels and enhancing endothelial function. 34 However, lipid profiles were not significant at the 12 month time point which suggests that other measures need to be added later on during the treatment course of dyslipidaemia.
Our participants' blood pressure (BP) values were less than 125mmHg which is in line to the NKF guidelines for CKD. The blood pressure values of patients in Group SU did not show any significant difference when compared to Group SU+DDP4i although there was a trend for lower values in patients receiving alogliptin. This is likely to be due to an increase in sodium excretion which leads to a reduction in blood volume. The latter suggests a renal protection property associated with the use of alogliptin. 35 Patients' weight measurements were statistically significant when Group SU and Group SU+DPP-4i were compared. There was a significant increase in the weight of patients belonging to the Group SU but not in the Group SU+DPP-4i. Theories about how weight gain is prevented in DPP-4i include explanations of enhanced postprandial lipid mobilization and oxidation by alogliptin. 36 This might be due to an increase in the postprandial thermogenesis. In the long term, the avoidance of weight gain can have indirect effects on cardiovascular risks including blood pressure, insulin resistance and cholesterol levels.
Renal function
A point of interest in the present study was to assess if using DPP-4i had a deleterious effect on renal function by estimating eGFR values in patients having mild renal disease. There was a significant (p<0.05) difference between the eGFR values in both groups with improved eGFR values in Group SU+DPP-4i. Previous studies have shown similar results. 31 Previous studies have shown a significant reduction of ACR values after 24 weeks post treatment with linagliptin. Nevertheless, HbA1 C values did not change and this suggested that the effect was likely to be independent of glycaemic control. 37 Although our study did not show a significant change in ACR or PCR values post DPP4i treatment, however eGFR improvement might suggest possible nephroprotective effects. The DPP4i exact nephroprotective role is still debated and has not been fully elucidated yet. However, a possible mechanism may include an improvement in the variability of blood glucose which is well known in inhibiting the progress of diabetes complications. 38 Studies on the effect of DDP4i, including animal studies, have suggested improved eGFR values, modulation of nephropathy and reduction of albumin levels independent of glycaemic control. 39 Furthermore, it has been proposed by in vitro data that glucagon-like peptide-1 (GLP-1) receptor expression in the kidneys is high. This makes the kidney a feasible organ for DPP-4 activity and a target in the extra-pancreatic effects of incretins. It has also been shown that upregulation of DPP4 expression in the renal glomeruli during inflammation, contributed to the development of diabetes-induced glomerulosclerosis. Studies have shown that using DPP-4i increased the local levels of GLP-1 in the kidneys which promoted anti-inflammation and anti-oxidation. 40 Indeed, if future larger prospective clinical studies could confirm DPP4i nephroprotective role and its ability to reduce albumin levels especially, this would be an important progress in clinical practice involving diabetic CKD patients.
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Conclusion
In summary, it can be concluded that DPP-4 inhibitors are effective and safe treatment options for patients with type 2 diabetes and mild degree of renal impairment. Using alogliptin in such patients as add on treatment to sulfonyl urea, resulted in an improved glycaemic control, and lipid profile that did not increase the chance of hypoglycaemic episodes. 
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